HEADER TRANSCRIPTION 13-MAR-12 4E4K TITLE CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND JO21 CAVEAT 4E4K THE LIGANDS RRG 501, 502 A HAVE HIGH REAL-SPACE R-VALUES AND CAVEAT 2 4E4K LOW CORRELATION COEFFICIENTS. COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN (UNP RESIDUES 223-505); COMPND 5 SYNONYM: PPAR-GAMMA, NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C MEMBER 3; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARG, NR1C3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET28A KEYWDS BUNDLE OF ALPHA-HELICES AND A SMALL FOUR-STRANDED BETA-SHEET, KEYWDS 2 TRANSCRIPTION FACTOR, TRANSCRIPTION EXPDTA X-RAY DIFFRACTION AUTHOR G.POCHETTI,R.MONTANARI,F.LOIODICE,G.FRACCHIOLLA,A.LAGHEZZA, AUTHOR 2 G.CARBONARA,L.PIEMONTESE,A.LAVECCHIA,E.NOVELLINO REVDAT 1 23-JAN-13 4E4K 0 JRNL AUTH A.LAGHEZZA,G.POCHETTI,A.LAVECCHIA,G.FRACCHIOLLA,S.FALITI, JRNL AUTH 2 L.PIEMONTESE,C.DI GIOVANNI,V.IACOBAZZI,V.INFANTINO, JRNL AUTH 3 R.MONTANARI,D.CAPELLI,P.TORTORELLA,F.LOIODICE JRNL TITL NEW 2-(ARYLOXY)-3-PHENYLPROPANOIC ACIDS AS PEROXISOME JRNL TITL 2 PROLIFERATOR-ACTIVATED RECEPTOR ALPHA/GAMMA DUAL AGONISTS JRNL TITL 3 ABLE TO UPREGULATE MITOCHONDRIAL CARNITINE SHUTTLE SYSTEM JRNL TITL 4 GENE EXPRESSION. JRNL REF J.MED.CHEM. V. 56 60 2013 JRNL REFN ISSN 0022-2623 JRNL PMID 23171045 JRNL DOI 10.1021/JM301018Z REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH R.MONTANARI,F.SACCOCCIA,E.SCOTTI,M.CRESTANI,C.GODIO, REMARK 1 AUTH 2 F.GILARDI,F.LOIODICE,G.FRACCHIOLLA,A.LAGHEZZA,P.TORTORELLA, REMARK 1 AUTH 3 A.LAVECCHIA,E.NOVELLINO,F.MAZZA,M.ASCHI,G.POCHETTI REMARK 1 TITL CRYSTAL STRUCTURE OF THE PEROXISOME PROLIFERATOR-ACTIVATED REMARK 1 TITL 2 RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A NOVEL REMARK 1 TITL 3 PARTIAL AGONIST: A NEW REGION OF THE HYDROPHOBIC POCKET REMARK 1 TITL 4 COULD BE EXPLOITED FOR DRUG DESIGN REMARK 1 REF J.MED.CHEM. V. 51 7768 2008 REMARK 1 REFN ISSN 0022-2623 REMARK 1 PMID 19053776 REMARK 1 DOI 10.1021/JM800733H REMARK 1 REFERENCE 2 REMARK 1 AUTH Y.LI,Z.WANG,N.FURUKAWA,P.ESCARON,J.WEISZMANN,G.LEE, REMARK 1 AUTH 2 M.LINDSTROM,J.LIU,X.LIU,H.XU,O.PLOTNIKOVA,V.PRASAD,N.WALKER, REMARK 1 AUTH 3 R.M.LEARNED,J.L.CHEN REMARK 1 TITL T2384, A NOVEL ANTIDIABETIC AGENT WITH UNIQUE PEROXISOME REMARK 1 TITL 2 PROLIFERATOR-ACTIVATED RECEPTOR GAMMA BINDING PROPERTIES REMARK 1 REF J.BIOL.CHEM. V. 283 9168 2008 REMARK 1 REFN ISSN 0021-9258 REMARK 1 PMID 18263587 REMARK 1 DOI 10.1074/JBC.M800104200 REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 22770 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.265 REMARK 3 FREE R VALUE : 0.335 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 1095 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4298 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 54 REMARK 3 SOLVENT ATOMS : 134 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 53.16 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.009 REMARK 3 BOND ANGLES (DEGREES) : 1.31 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: THE ELECTRON DENSITY IN THE REGION OF REMARK 3 THE LIGANDS RRG 501 AND RRG 502 WAS WEAK. IT IS POSSIBLE THAT THE REMARK 3 LIGANDS ARE DISORDERED. THE DETAILS OF LIGAND MODELING ARE REMARK 3 DESCRIBED IN THE MANUSCRIPT. REMARK 4 REMARK 4 4E4K COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 23-MAR-12. REMARK 100 THE RCSB ID CODE IS RCSB071160. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 06-MAY-10 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID23-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.873 REMARK 200 MONOCHROMATOR : SI(111) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 225 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 23188 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.500 REMARK 200 RESOLUTION RANGE LOW (A) : 45.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 200 DATA REDUNDANCY : 3.800 REMARK 200 R MERGE (I) : 0.06500 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 12.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.64 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 3.80 REMARK 200 R MERGE FOR SHELL (I) : 0.44900 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 52.08 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.57 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.8M NACITRATE, 0.15M TRIS, PH8.0, REMARK 280 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293 KK REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 46.50500 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 31.06000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 46.50500 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 31.06000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2080 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 25570 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -11.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 2 1.000000 0.000000 0.000000 -46.50500 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 31.06000 REMARK 350 BIOMT3 2 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 191 REMARK 465 SER A 192 REMARK 465 HIS A 193 REMARK 465 MET A 194 REMARK 465 ALA A 195 REMARK 465 GLU A 196 REMARK 465 ILE A 197 REMARK 465 SER A 198 REMARK 465 SER A 199 REMARK 465 ASP A 200 REMARK 465 ILE A 201 REMARK 465 ASP A 202 REMARK 465 GLN A 203 REMARK 465 LEU A 204 REMARK 465 ASN A 205 REMARK 465 PRO A 206 REMARK 465 ASP A 475 REMARK 465 LEU A 476 REMARK 465 TYR A 477 REMARK 465 GLY B 191 REMARK 465 SER B 192 REMARK 465 HIS B 193 REMARK 465 MET B 194 REMARK 465 ALA B 195 REMARK 465 GLU B 196 REMARK 465 ILE B 197 REMARK 465 SER B 198 REMARK 465 SER B 199 REMARK 465 ASP B 200 REMARK 465 ILE B 201 REMARK 465 ASP B 202 REMARK 465 GLN B 203 REMARK 465 LEU B 204 REMARK 465 ASN B 205 REMARK 465 PRO B 206 REMARK 465 ASP B 475 REMARK 465 LEU B 476 REMARK 465 TYR B 477 REMARK 475 REMARK 475 ZERO OCCUPANCY RESIDUES REMARK 475 THE FOLLOWING RESIDUES WERE MODELED WITH ZERO OCCUPANCY. REMARK 475 THE LOCATION AND PROPERTIES OF THESE RESIDUES MAY NOT REMARK 475 BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 475 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE) REMARK 475 M RES C SSEQI REMARK 475 GLU B 259 REMARK 475 ASP B 260 REMARK 475 ARG B 357 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 240 -77.31 -61.30 REMARK 500 THR A 241 92.03 -68.95 REMARK 500 THR A 242 58.19 -103.52 REMARK 500 LYS A 244 97.26 -179.19 REMARK 500 HIS A 266 173.50 -55.49 REMARK 500 THR A 268 -50.80 -132.32 REMARK 500 PRO A 269 -134.64 -57.88 REMARK 500 GLN A 271 -46.86 -131.31 REMARK 500 GLU A 272 -34.94 -39.09 REMARK 500 LYS A 275 76.73 69.37 REMARK 500 GLU A 276 168.83 -46.34 REMARK 500 LEU A 309 159.20 -36.56 REMARK 500 LYS A 336 -7.82 -46.67 REMARK 500 ARG A 357 175.23 -47.78 REMARK 500 PRO A 359 -86.00 -73.29 REMARK 500 PHE A 360 -51.24 -26.36 REMARK 500 SER A 394 -75.02 -89.82 REMARK 500 ASP A 396 21.82 -66.76 REMARK 500 LEU A 401 -73.47 -48.58 REMARK 500 VAL A 403 -59.90 -124.13 REMARK 500 GLU A 427 30.88 -67.99 REMARK 500 SER A 464 -139.33 -107.72 REMARK 500 LEU A 465 110.70 168.63 REMARK 500 PRO B 227 -73.19 -59.98 REMARK 500 LEU B 237 -149.99 -57.71 REMARK 500 LYS B 240 -81.96 -72.12 REMARK 500 THR B 241 54.21 24.53 REMARK 500 LYS B 244 68.77 -173.76 REMARK 500 MET B 257 10.28 -56.95 REMARK 500 LYS B 261 -7.04 -174.97 REMARK 500 LYS B 263 77.52 -43.26 REMARK 500 HIS B 266 -96.86 172.99 REMARK 500 GLU B 272 98.42 163.73 REMARK 500 GLN B 273 4.99 57.05 REMARK 500 LYS B 275 172.28 56.85 REMARK 500 SER B 342 77.86 42.65 REMARK 500 GLU B 343 25.76 48.78 REMARK 500 LYS B 354 -6.42 -54.76 REMARK 500 LEU B 356 -43.04 -154.71 REMARK 500 ARG B 357 -142.60 178.63 REMARK 500 PRO B 359 36.02 -82.86 REMARK 500 PHE B 360 -53.49 -148.21 REMARK 500 MET B 364 -84.41 -63.37 REMARK 500 GLU B 365 -58.48 -11.44 REMARK 500 SER B 394 -88.84 -65.19 REMARK 500 THR B 459 -124.55 -146.38 REMARK 500 THR B 461 -92.74 -139.37 REMARK 500 ASP B 462 90.93 -66.83 REMARK 500 PRO B 467 -75.33 -62.59 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE RRG A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE RRG A 502 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3B3K RELATED DB: PDB REMARK 900 THE SAME PROTEIN COMPLEXED WITH LT175 REMARK 900 RELATED ID: 3K8S RELATED DB: PDB REMARK 900 THE SAME PROTEIN COMPLEXED WITH T2384 REMARK 900 RELATED ID: 4E4Q RELATED DB: PDB DBREF 4E4K A 195 477 UNP P37231 PPARG_HUMAN 223 505 DBREF 4E4K B 195 477 UNP P37231 PPARG_HUMAN 223 505 SEQADV 4E4K GLY A 191 UNP P37231 EXPRESSION TAG SEQADV 4E4K SER A 192 UNP P37231 EXPRESSION TAG SEQADV 4E4K HIS A 193 UNP P37231 EXPRESSION TAG SEQADV 4E4K MET A 194 UNP P37231 EXPRESSION TAG SEQADV 4E4K GLY B 191 UNP P37231 EXPRESSION TAG SEQADV 4E4K SER B 192 UNP P37231 EXPRESSION TAG SEQADV 4E4K HIS B 193 UNP P37231 EXPRESSION TAG SEQADV 4E4K MET B 194 UNP P37231 EXPRESSION TAG SEQRES 1 A 287 GLY SER HIS MET ALA GLU ILE SER SER ASP ILE ASP GLN SEQRES 2 A 287 LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU ALA LYS SEQRES 3 A 287 HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO LEU THR SEQRES 4 A 287 LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS THR THR SEQRES 5 A 287 ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SER LEU SEQRES 6 A 287 MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS ILE THR SEQRES 7 A 287 PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE ARG ILE SEQRES 8 A 287 PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA VAL GLN SEQRES 9 A 287 GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY PHE VAL SEQRES 10 A 287 ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS TYR SEQRES 11 A 287 GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SER LEU SEQRES 12 A 287 MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY GLN GLY SEQRES 13 A 287 PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG LYS PRO SEQRES 14 A 287 PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE ALA VAL SEQRES 15 A 287 LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU ALA SEQRES 16 A 287 ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP ARG PRO SEQRES 17 A 287 GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP SEQRES 18 A 287 ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN SEQRES 19 A 287 HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU LEU GLN SEQRES 20 A 287 LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU HIS VAL SEQRES 21 A 287 GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR ASP MET SEQRES 22 A 287 SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU SEQRES 23 A 287 TYR SEQRES 1 B 287 GLY SER HIS MET ALA GLU ILE SER SER ASP ILE ASP GLN SEQRES 2 B 287 LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU ALA LYS SEQRES 3 B 287 HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO LEU THR SEQRES 4 B 287 LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS THR THR SEQRES 5 B 287 ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SER LEU SEQRES 6 B 287 MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS ILE THR SEQRES 7 B 287 PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE ARG ILE SEQRES 8 B 287 PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA VAL GLN SEQRES 9 B 287 GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY PHE VAL SEQRES 10 B 287 ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS TYR SEQRES 11 B 287 GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SER LEU SEQRES 12 B 287 MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY GLN GLY SEQRES 13 B 287 PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG LYS PRO SEQRES 14 B 287 PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE ALA VAL SEQRES 15 B 287 LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU ALA SEQRES 16 B 287 ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP ARG PRO SEQRES 17 B 287 GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP SEQRES 18 B 287 ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN SEQRES 19 B 287 HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU LEU GLN SEQRES 20 B 287 LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU HIS VAL SEQRES 21 B 287 GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR ASP MET SEQRES 22 B 287 SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU SEQRES 23 B 287 TYR HET RRG A 501 27 HET RRG A 502 27 HETNAM RRG (2S)-3-PHENYL-2-{[2'-(PROPAN-2-YL)BIPHENYL-4- HETNAM 2 RRG YL]OXY}PROPANOIC ACID FORMUL 3 RRG 2(C24 H24 O3) FORMUL 5 HOH *134(H2 O) HELIX 1 1 SER A 208 PHE A 226 1 19 HELIX 2 2 THR A 229 THR A 238 1 10 HELIX 3 3 ASP A 251 GLU A 259 1 9 HELIX 4 4 GLU A 276 SER A 302 1 27 HELIX 5 5 ASP A 310 LEU A 330 1 21 HELIX 6 6 ARG A 350 SER A 355 1 6 HELIX 7 7 PRO A 359 PHE A 363 5 5 HELIX 8 8 MET A 364 ASN A 375 1 12 HELIX 9 9 ALA A 376 GLU A 378 5 3 HELIX 10 10 ASP A 380 LEU A 393 1 14 HELIX 11 11 VAL A 403 HIS A 425 1 23 HELIX 12 12 GLN A 430 GLU A 460 1 31 HELIX 13 13 HIS A 466 TYR A 473 1 8 HELIX 14 14 SER B 208 PHE B 226 1 19 HELIX 15 15 THR B 229 LEU B 237 1 9 HELIX 16 16 ASP B 251 ASP B 260 1 10 HELIX 17 17 GLU B 276 SER B 302 1 27 HELIX 18 18 ASP B 310 LEU B 333 1 24 HELIX 19 19 ARG B 350 LYS B 354 1 5 HELIX 20 20 MET B 364 ALA B 376 1 13 HELIX 21 21 ASP B 380 LEU B 393 1 14 HELIX 22 22 ASN B 402 HIS B 425 1 24 HELIX 23 23 GLN B 430 GLN B 437 1 8 HELIX 24 24 LYS B 438 ILE B 456 1 19 HELIX 25 25 LYS B 457 THR B 459 5 3 HELIX 26 26 HIS B 466 TYR B 473 1 8 SHEET 1 A 4 PHE A 247 ILE A 249 0 SHEET 2 A 4 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 A 4 GLY A 338 ILE A 341 -1 N VAL A 339 O MET A 348 SHEET 4 A 4 MET A 334 ASN A 335 -1 N ASN A 335 O GLY A 338 SHEET 1 B 4 PHE B 247 ILE B 249 0 SHEET 2 B 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 B 4 GLY B 338 ILE B 341 -1 N VAL B 339 O MET B 348 SHEET 4 B 4 MET B 334 ASN B 335 -1 N ASN B 335 O GLY B 338 SITE 1 AC1 14 PHE A 264 HIS A 266 PHE A 282 CYS A 285 SITE 2 AC1 14 ARG A 288 TYR A 327 LEU A 330 ILE A 341 SITE 3 AC1 14 SER A 342 PHE A 363 MET A 364 LYS A 367 SITE 4 AC1 14 RRG A 502 HOH A 646 SITE 1 AC2 17 PHE A 282 GLN A 283 CYS A 285 GLN A 286 SITE 2 AC2 17 SER A 289 HIS A 323 ILE A 326 TYR A 327 SITE 3 AC2 17 PHE A 363 HIS A 449 LEU A 453 ILE A 456 SITE 4 AC2 17 MET A 463 LEU A 469 TYR A 473 RRG A 501 SITE 5 AC2 17 HOH A 607 CRYST1 93.010 62.120 118.980 90.00 102.42 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010752 0.000000 0.002368 0.00000 SCALE2 0.000000 0.016098 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008606 0.00000 MASTER 386 0 2 26 8 0 9 6 0 0 0 46 END